Normal vision. Courtesy NIH National Eye InstituteThe same view with tunnel vision from retinitis pigmentosa
Find information on thousands of medical conditions and prescription drugs.

Retinitis pigmentosa

Retinitis pigmentosa, or RP, is a genetic eye condition. Generally, night blindness precedes tunnel vision by years or even decades. Many people with RP do not become legally blind until their 40s or 50s and retain some sight all their life. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
Gastroesophageal reflux...
Rabies
Radiophobia
Rasmussen's encephalitis
Raynaud's phenomenon
Reactive arthritis
Reactive hypoglycemia
Reflex sympathetic...
Regional enteritis
Reiter's Syndrome
Renal agenesis
Renal artery stenosis
Renal calculi
Renal cell carcinoma
Renal cell carcinoma
Renal cell carcinoma
Renal failure
Renal osteodystrophy
Renal tubular acidosis
Repetitive strain injury
Respiratory acidosis
Restless legs syndrome
Retinitis pigmentosa
Retinoblastoma
Retinoschisis
Retrolental fibroplasia
Retroperitoneal fibrosis
Rett syndrome
Reye's syndrome
Rh disease
Rhabdomyolysis
Rhabdomyosarcoma
Rheumatic fever
Rheumatism
Rheumatoid arthritis
Rickets
Rift Valley fever
Ringworm
Rocky Mountain spotted fever
Romano-Ward syndrome
Roseola infantum
Rubella
Rubeola
Rubinstein-Taybi syndrome
Rumination disorder
S
T
U
V
W
X
Y
Z
Medicines

Others go completely blind from RP, in some cases as early as childhood. Progression of RP is different in each case.

RP is a group of inherited disorders in which abnormalities of the photoreceptors (rods and cones) or the retinal pigment epithelium (RPE) of the retina lead to progressive visual loss. Affected individuals first experience defective dark adaptation or nyctalopia (night blindness), followed by constriction of the peripheral visual field and, eventually, loss of central vision late in the course of the disease.

Signs

Mottling of the retinal pigment epithelium with bone-spicule pigmentation is typically pathognomonic for retinis pigmentosa. Other ocular features include waxy pallor of the optic nerve head, attenuated retinal vessels, cellophane maculopathy, cystic macular edema, and posterior subcapsular cataract.

Diagnosis

The diagnosis of RP relies upon documentation of progressive loss in photoreceptor function by electroretinography (ERG) and visual field testing. The mode of inheritance of RP is determined by family history. At least 35 different genes or loci are known to cause nonsyndromic RP. DNA testing is available on a clinical basis for RLBP1 (autosomal recessive, Bothnia type RP), RP1 (autosomal dominant, RP1), RHO (autosomal dominant, RP4), RDS (autosomal dominant, RP7), PRPF8 (autosomal dominant, RP13), PRPF3 (autosomal dominant, RP18), CRB1 (autosomal recessive, RP12), ABCA4 (autosomal recessive, RP19), and RPE65 (autosomal recessive, RP20). For all other genes, molecular genetic testing is available on a research basis only.

RP can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. X-linked RP can be either recessive, affecting primarily only males, or dominant, affecting both males and females, although females are always more mildly affected. Some digenic and mitochondrial forms have also been described. Genetic counseling depends on an accurate diagnosis, determination of the mode of inheritance in each family, and results of molecular genetic testing. RP combined with progressive deafness is called Usher syndrome.

Treatment

There is currently no medical treatment for retinitis pigmentosa, although scientists continue to investigate possible treatments. Future treatments may involve retinal transplants, artificial retinal implants , gene therapy, stem cells, nutritional supplements, and/or drug therapies.

Sources

Jones BW, CB Watt, JM Frederick, W Baehr, CK Chen, EM Levine, AH Milam, MM LaVail, RE Marc 2003 Retinal remodeling triggered by photoreceptor degenerations. J Comp Neurol 464: 1-16.

Marc RE, BW Jones 2003 Retinal remodeling in inherited photoreceptor degenerations. Molecular Neurobiology 28: 139-148.

Read more at Wikipedia.org


[List your site here Free!]


Vitamin slows advancing blindness from RP - Vitamin A, retinitis pigmentosa
From Science News, 6/19/93 by Janet Raloff

It starts as an inability to distinguish features at night. Before long, retinitis pigmentosa (RP) leaves its victims with tunnel vision or no sight at all. Though a cure for this inherited disease remains elusive, Boston-area researchers reported this week what appears to be the first successful treatment. Large daily supplements of a particularly stable form of vitamin A slowed the inexorable degeneration of retinal function that characterizes RP.

"This is exciting news;' says Carl Kupfer, director of the National Eye Institute in Bethesda, Md. Worldwide, roughly one in every 4,000 persons suffers from the disease.

Adds Alan M. Laties, chairman of the RP Foundation's scientific advisory board, "Although not a cure, [vitamin A supplementation] will improve the quality of life, potentially adding many years of useful vision."

While monitoring RP patients in the early 1980s, ophthalmologist Eliot L. Berson and his co-workers identified a small group who had been supplementing their diet with large amounts of vitamin A, vitamin E, or both. And compared to patients taking ordinary multivitamin supplements or no supplements at all, those taking high doses of A or E sustained far less retinal degeneration over a two-year span, as measured by an electroretinogram (ERG). This test determines the health of photoreceptors by measuring electrical activity o! the eye's photoreceptor cells, known as rods and cones.

The finding intrigued Berson, of the Berman-Gund Laboratory for the Study of Retinal Degenerations at Harvard Medical School in Boston, because high ERG values correlate with healthy photoreceptors. However, since most of the megavitamin users took both A and E, Berson's team couldn't determine the relative value of the vitamins.

So they initiated a six-year study of 601 RP patients between age 18 and 49. The researchers randomly assigned each patient to one of four daily supplements: 15,000 international units (IU) of vitamin A in the form of retinyI palmitate; 15,000 IU of A plus 400 IU of vitamin E; 400 IU of vitamin E; or trace amounts of both vitamins. Annually, the Harvard researchers assessed ERG values, visual field (peripheral vision), and visual acuity in each patient. Neither patients nor doctors knew which treatment any individual had received.

In the June ARCHIVES OF OPHTHALMOLOGY, Berson's team reports finding a slower drop-off in ERG values among patients receiving 15,000 IU of vitamin A. Those getting large amounts of both vitamins did less well, but better than patients receiving just trace amounts of each.

The big surprise, Berson says, was that retinal degeneration proceeded most quickly in patients given vitamin E supplements. Although the data weren't powerful enough to prove that E posed a risk to patients with the most advanced retinal degeneration at the start of the study, Berson says that "anybody reading this paper would conclude that RP patients shouldn't take high doses of E:'

Overall, the new data suggest, the average RP patient in this study beginning vitamin A therapy at age 32 will retain some useful vision until age 70 -- seven years longer than one taking no supplements and 12 years longer than a patient taking 400 lU of vitamin E daily, Though the Harvard researchers now recommend vitamin A therapy for most RP patients, they caution against taking any form but the palmirate - and then only under an ophthalmologist's supervision.

Vitamin A plays a functional role in sight by latching on to a protein in the rods and cones. When exposed to light, the vitamin changes shape -- the initial step in relaying light-detection signals t0 the brain. "But the mechanism by which vitamin A helps the retina in this disease remains unknown." Berson notes. Vitamin E's role also remains unknown, although Berson's group observed that patients taking vitamin E had lower concentrations of A in their blood, suggesting that E may inhibit the body's absorption or transport of A.

In an accompanying editorial, Robert M. Massof and Daniel Finkelstein of Johns Hopkins University in Baltimore describe the new study as "a tour de force in experimental design, execution, and statistical analysis." However, they advise caution in prescribing vitamin A, arguing that the slower declines in ERG readings of A-supplemented patients may not necessarily translate into a slowing o! their loss of visual function.

Berson disagrees. "The editorial implies that visual field is the last word on how people are doing," he told ScIENcE NEws. "But electrical recording should be the last word -- because it's much more sensitive." Indeed, he argues, ERG data are so sensitive they can detect changes that may take 10 or 15 years to confirm through visual-field tests.

COPYRIGHT 1993 Science Service, Inc.
COPYRIGHT 2004 Gale Group

Return to Retinitis pigmentosa
Home Contact Resources Exchange Links ebay